When to Stop Propranolol for Infantile Hemangioma

Overview

Journal Sci Rep

Specialty Science

Date 2017 Feb 23

PMID 28225076

Citations 11

Authors

Lei Chang

Yifei Gu

Zhang Yu

Hanru Ying

Yajing Qiu

Gang Ma

Hui Chen

Yunbo Jin

Xiaoxi Lin

Affiliations

Soon will be listed here.

Abstract

There is no definitive conclusion regarding the optimal timing for terminating propranolol treatment for infantile hemangioma (IH). A total of 149 patients who underwent detailed color Doppler ultrasound examination were included in this study. The characteristics and propranolol treatment of all patients were summarized and analyzed. Patients were divided into two groups according to the lesion regression rate. Among the 149 patients, 38 were assigned to the complete regression group, and 111 were assigned to the partial regression group. The age at which propranolol treatment started, duration of follow-up after treatment discontinuation and rate of adverse events were not significantly different between the two groups. The duration of oral propranolol treatment was shorter in the complete regression group. The age at which propranolol was terminated was younger in the complete regression group, and this group had a lower recurrence rate. Propranolol is safe and effective for the treatment of IHs that require intervention, but it should be stopped at an appropriate time, which is determined primarily by the lesion regression rate after propranolol treatment. Ultrasound is helpful in determining when to stop propranolol for IH.

Citing Articles

Optimizing Propranolol Therapy for Infantile Hemangiomas: The Role of the Multidisciplinary Team.

Yasuda-Koiwa M, Ogawa T, Ogawa A, Takizawa F, Mukoyama Y, Moriguchi S Cureus. 2025; 16(12):e75806.

PMID: 39822455 PMC: 11735240. DOI: 10.7759/cureus.75806.

Efficacy and safety of oral propranolol and topical timolol in the treatment of infantile hemangioma: a meta-analysis and systematic review.

Huang X, Si W, Zou Z, Li B, Mu Y, Zhong W Front Pharmacol. 2024; 15:1515901.

PMID: 39687294 PMC: 11646719. DOI: 10.3389/fphar.2024.1515901.

Practical surgical technique using the SMISS approach for lip reduction in involuted lip infantile hemangiomas.

Chen Q, Chang S, Gao W, Chang L, Qiu Y, Lin X BMC Pediatr. 2024; 24(1):368.

PMID: 38807073 PMC: 11131259. DOI: 10.1186/s12887-024-04838-4.

Infantile Hemangiomas Lose Vascular Endothelial Cadherin During Involution: Potential Role in Cell Death?.

Clapp A, Modiri O, Schonning M, Wu J Plast Reconstr Surg Glob Open. 2024; 12(5):e5832.

PMID: 38798935 PMC: 11124740. DOI: 10.1097/GOX.0000000000005832.

Propranolol for Vascular Anomalies: Efficacy and Complications in Pediatric Patients.

Gupta R J Indian Assoc Pediatr Surg. 2023; 28(3):194-205.

PMID: 37389387 PMC: 10305951. DOI: 10.4103/jiaps.jiaps_117_22.

References

Ji Y, Wang Q, Chen S, Xiang B, Xu Z, Li Y . Oral atenolol therapy for proliferating infantile hemangioma: A prospective study. Medicine (Baltimore). 2016; 95(24):e3908. PMC: 4998480. DOI: 10.1097/MD.0000000000003908. View

Menapace D, Mitkov M, Towbin R, Hogeling M . The changing face of complicated infantile hemangioma treatment. Pediatr Radiol. 2016; 46(11):1494-506. DOI: 10.1007/s00247-016-3643-6. View

Sagi L, Zvulunov A, Lapidoth M, Ben Amitai D . Efficacy and safety of propranolol for the treatment of infantile hemangioma: a presentation of ninety-nine cases. Dermatology. 2014; 228(2):136-44. DOI: 10.1159/000351557. View

Moyakine A, Kerstjens J, Spillekom-van Koulil S, van der Vleuten C . Propranolol treatment of infantile hemangioma (IH) is not associated with developmental risk or growth impairment at age 4 years. J Am Acad Dermatol. 2016; 75(1):59-63.e1. DOI: 10.1016/j.jaad.2016.02.1218. View

Tozzi A . Oral Propranolol for Infantile Hemangioma. N Engl J Med. 2015; 373(3):284. DOI: 10.1056/NEJMc1503811. View

Chen Z, Zheng J, Zhang L, Zhu L, Wang Y . A survey on clinical use of propranolol for infantile hemangiomas in mainland China. Int J Clin Exp Med. 2015; 8(2):2138-46. PMC: 4402791. View

Hermans D, Bauland C, Zweegers J, van Beynum I, van der Vleuten C . Propranolol in a case series of 174 patients with complicated infantile haemangioma: indications, safety and future directions. Br J Dermatol. 2013; 168(4):837-43. DOI: 10.1111/bjd.12189. View

MacIsaac Z, Nayar H, Gehris R, Mehta D, Geisler S, Grunwaldt L . Treatment for Infantile Hemangiomas: Selection Criteria, Safety, and Outcomes Using Oral Propranolol During the Early Phase of Propranolol Use for Hemangiomas. J Craniofac Surg. 2015; 27(1):159-62. DOI: 10.1097/SCS.0000000000002206. View

Holmes W, Mishra A, Gorst C, Liew S . Propranolol as first-line treatment for rapidly proliferating infantile haemangiomas. J Plast Reconstr Aesthet Surg. 2010; 64(4):445-51. DOI: 10.1016/j.bjps.2010.07.009. View

10.

Wortsman X, Wortsman J . Clinical usefulness of variable-frequency ultrasound in localized lesions of the skin. J Am Acad Dermatol. 2009; 62(2):247-56. DOI: 10.1016/j.jaad.2009.06.016. View

11.

Bingham M, Saltzman B, Vo N, Perkins J . Propranolol reduces infantile hemangioma volume and vessel density. Otolaryngol Head Neck Surg. 2012; 147(2):338-44. DOI: 10.1177/0194599812451570. View

12.

Talaat A, Elbasiouny M, Elgendy D, Elwakil T . Propranolol treatment of infantile hemangioma: clinical and radiologic evaluations. J Pediatr Surg. 2012; 47(4):707-14. DOI: 10.1016/j.jpedsurg.2011.10.058. View

13.

Leaute-Labreze C, Hoeger P, Mazereeuw-Hautier J, Guibaud L, Baselga E, Posiunas G . A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015; 372(8):735-46. DOI: 10.1056/NEJMoa1404710. View

14.

Tan S, Itinteang T, Leadbitter P . Low-dose propranolol for infantile haemangioma. J Plast Reconstr Aesthet Surg. 2010; 64(3):292-9. DOI: 10.1016/j.bjps.2010.06.010. View

15.

Fay A, Nguyen J, Waner M . Conceptual approach to the management of infantile hemangiomas. J Pediatr. 2010; 157(6):881-8.e1-5. DOI: 10.1016/j.jpeds.2010.08.013. View

16.

Hoeger P, Harper J, Baselga E, Bonnet D, Boon L, Ciofi Degli Atti M . Treatment of infantile haemangiomas: recommendations of a European expert group. Eur J Pediatr. 2015; 174(7):855-65. DOI: 10.1007/s00431-015-2570-0. View

17.

Shi H, Song H, Wang J, Xia L, Yang J, Shang Y . Ultrasound in assessing the efficacy of propranolol therapy for infantile hemangiomas. Ultrasound Med Biol. 2014; 40(11):2622-9. DOI: 10.1016/j.ultrasmedbio.2014.06.021. View

18.

Shehata N, Powell J, Dubois J, Hatami A, Rousseau E, Ondrejchak S . Late rebound of infantile hemangioma after cessation of oral propranolol. Pediatr Dermatol. 2013; 30(5):587-91. DOI: 10.1111/pde.12190. View

19.

Szychta P, Stewart K, Anderson W . Treatment of infantile hemangiomas with propranolol: clinical guidelines. Plast Reconstr Surg. 2013; 133(4):852-862. DOI: 10.1097/PRS.0000000000000007. View

20.

Kilcline C, Frieden I . Infantile hemangiomas: how common are they? A systematic review of the medical literature. Pediatr Dermatol. 2008; 25(2):168-73. DOI: 10.1111/j.1525-1470.2008.00626.x. View